Matthew J. Sorrentino, MD
To the Editors: In their review of the selection of patients with acute myocardial infarction for thrombolytic therapy, Muller and Topol (1) pointed out the current limitations in applying this therapy to a larger number of patients. The decision to withhold thrombolytic therapy, however, is based not only on the recognition of risk factors but also on our inability to make an accurate and timely diagnosis of an acute myocardial infarction (2).
Eligibility criteria for thrombolytic trials have usually relied on a typical history of chest pain and specific electrocardiographic (ECG) findings of acute ischemia. Up to 50% of patients
Sorrentino MJ. Thrombolytic Therapy. Ann Intern Med. ;114:521. doi: 10.7326/0003-4819-114-6-521_1
Download citation file:
Published: Ann Intern Med. 1991;114(6):521.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use